HER-2 directed therapies across gastrointestinal tract cancers - A new frontier.
Date
2024-09-01Author
Jones, L
Cunningham, D
Starling, N
Type
Journal Article
Metadata
Show full item recordAbstract
Gastrointestinal (GI) cancers are common and in the metastatic setting they have a poor prognosis. The current mainstay of treatment of GI cancers is chemotherapy; however, the biomarker-directed treatment landscape is evolving. HER-2 is overexpressed in a portion of GI cancers and is an emerging target for therapy, with recent FDA tumor agnostic approval for trastuzumab deruxtecan. Testing for HER-2 expression is not standardized across GI cancers, methodology requires further optimization and standardization as HER-2 targeted therapy emerges into the treatment landscape. There is established rationale for use of HER-2 targeted therapy in first line treatment of metastatic gastric cancer, and emerging evidence with variable benefit in bile duct, pancreatic and colorectal cancers.
Collections
Subject
Biliary cancer
Colorectal cancer
Gastric cancer
Gastrointestinal cancer
HER-2
Pancreatic cancer
Humans
Gastrointestinal Neoplasms
Receptor, ErbB-2
Molecular Targeted Therapy
Trastuzumab
Antibodies, Monoclonal, Humanized
Antineoplastic Agents, Immunological
Camptothecin
Immunoconjugates
Research team
Medicine (RMH)
Language
eng
Date accepted
2024-06-18
License start date
2024-09-01
Citation
Cancer Treatment Reviews, 2024, 129 pp. 102789 -
Publisher
ELSEVIER SCI LTD
Except where otherwise noted, this item's license is described
as
http://creativecommons.org/licenses/by/4.0/
Related items
Showing items related by title, author, creator and subject.
-
Estimated impact of the COVID-19 pandemic on cancer services and excess 1-year mortality in people with cancer and multimorbidity: near real-time data on cancer care, cancer deaths and a population-based cohort study.
Lai, AG; Pasea, L; Banerjee, A; Hall, G; Denaxas, S; et al. (BMJ PUBLISHING GROUP, 2020-11-17)OBJECTIVES: To estimate the impact of the COVID-19 pandemic on cancer care services and overall (direct and indirect) excess deaths in people with cancer. METHODS: We employed near real-time weekly data on cancer care to ... -
Cross-Cancer Genome-Wide Association Study of Endometrial Cancer and Epithelial Ovarian Cancer Identifies Genetic Risk Regions Associated with Risk of Both Cancers.
Glubb, DM; Thompson, DJ; Aben, KKH; Alsulimani, A; Amant, F; et al. (AMER ASSOC CANCER RESEARCH, 2021-01-01)BACKGROUND: Accumulating evidence suggests a relationship between endometrial cancer and ovarian cancer. Independent genome-wide association studies (GWAS) for endometrial cancer and ovarian cancer have identified 16 and ... -
Can routine data be used to support cancer clinical trials? A historical baseline on which to build: retrospective linkage of data from the TACT (CRUK 01/001) breast cancer trial and the National Cancer Data Repository.
Kilburn, LS; Aresu, M; Banerji, J; Barrett-Lee, P; Ellis, P; et al. (BMC, 2017-11-23)BACKGROUND: Randomised clinical trials (RCTs) are the gold standard for evaluating new cancer treatments. They are, however, expensive to conduct, particularly where long-term follow-up of participants is required. Tracking ...